Tags : Alliance

Biotech

Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration

Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D […]Read More

Biosimilars

Samsung Biologics and AstraZeneca to Dissolve Rituximab Alliance

Shots: Samsung Biologics and AstraZeneca had decided to suspend long-running research and development activities by a jointly-owned subsidiary, Archigen Biotech, which was solely engaged in the development of SAIT101 (biosimilar, rituximab) Samsung halted the P-III study of SAIT101 in Oct’2012 and resumed it in 2014 via Archigen. The P-III study similar therapeutic effect to Rituxan […]Read More

Pharma

Gates Foundation Forms an Alliance with Global Pharma Companies to

Shots: GSK, Evotec, J&J, Otsuka, the Bill & Melinda Gates Medical Research Institute and its foundation have launched the ‘PAN-TB collaboration’ project to collaboratively accelerate the development of novel TB treatment regimens The global collaboration will focus on developing a new regimen with the drug candidates that demonstrated efficacy in its P-II studies with limited […]Read More

Pharma

Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista

Shots: Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities In Jul’2019, Sanofi has terminated its 4yrs. […]Read More